Literature DB >> 34144233

RASopathies: The musculoskeletal consequences and their etiology and pathogenesis.

John L Fowlkes1, Kathryn M Thrailkill2, R Clay Bunn2.   

Abstract

The RASopathies comprise an ever-growing number of clinical syndromes resulting from germline mutations in components of the RAS/MAPK signaling pathway. While multiple organs and tissues may be affected by these mutations, this review will focus on how these mutations specifically impact the musculoskeletal system. Herein, we review the genetics and musculoskeletal phenotypes of these syndromes in humans. We discuss how mutations in the RASopathy syndromes have been studied in translational mouse models. Finally, we discuss how signaling molecules within the RAS/MAPK pathway are involved in normal and abnormal bone biology in the context of osteoblasts, osteoclasts and chondrocytes.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Capillary malformation-arteriovenous malformation syndrome; Cardio-facio-cutaneous syndrome; Costello syndrome; Legius syndrome; Neurofibromatosis type 1; Noonan syndrome; RAS/MAPK pathway

Year:  2021        PMID: 34144233     DOI: 10.1016/j.bone.2021.116060

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  2 in total

1.  Identifying Bone Matrix Impairments in a Mouse Model of Neurofibromatosis Type 1 (NF1) by Clinically Translatable Techniques.

Authors:  Rafay Ahmed; Sasidhar Uppuganti; Shrey Derasari; Joshua Meyer; Jacquelyn S Pennings; Florent Elefteriou; Jeffry S Nyman
Journal:  J Bone Miner Res       Date:  2022-07-12       Impact factor: 6.390

Review 2.  Current Aspects on the Pathophysiology of Bone Metabolic Defects during Progression of Scoliosis in Neurofibromatosis Type 1.

Authors:  Angelos Kaspiris; Olga D Savvidou; Elias S Vasiliadis; Argyris C Hadjimichael; Dimitra Melissaridou; Stella Iliopoulou-Kosmadaki; Ilias D Iliopoulos; Evangelia Papadimitriou; Efstathios Chronopoulos
Journal:  J Clin Med       Date:  2022-01-15       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.